Search results for "EuP"

showing 10 items of 423 documents

Compliance to therapy with Dapoxetine in patients affected by Premature Ejaculation

2012

Introduction Premature ejaculation (PE) is a sexual dysfunction with high prevalence. According to some reports, it is present in about 20-30% of the male population. Since 2009 PE has been treated with a novel inhibitor of serotonin re-uptake, Dapoxetine, which has been reported to be specifically active for PE. Materials and Methods 59 patients have been selected among the patients affected by PE observed at the outpatient department of Urology and Andrology of the “Paolo Giaccone” University Policlinic Hospital of Palermo. Diagnosis was confirmed unequivocally in all patients, who were suitable for drug treatment and accepted to participate in the study. They were divided in 2 groups: on…

AdultMalemedicine.medical_specialtyBenzylaminespremature ejaculation dapoxetine Cytalopram compliance side effectsAdolescentGastrointestinal DiseasesMigraine DisordersComorbidityCitalopramCitalopramNaphthalenesMedication AdherenceSettore MED/24 - UrologiaDrug treatmentYoung AdultInternal medicineSurveys and QuestionnairesPremature ejaculationmedicineOutpatient clinicHumansIn patientPremature EjaculationEiaculazione precoce dapoxetina citalopram compliance effetti collateraliLife StyleAgedGynecologyHigh prevalencebusiness.industryGeneral MedicineMiddle AgedPatient Acceptance of Health CareDapoxetineSexual dysfunctionmedicine.symptomNervous System DiseasesbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders.

2012

Whether responses to antidepressants differ in bipolar and unipolar depression remains unresolved.We analyzed patient characteristics and outcomes of antidepressant treatment of 1036 depressed patients with bipolar-I or bipolar-II disorder, or unipolar major depression, using bivariate and multivariate methods and survival analysis, testing the hypothesis that responses would be superior in unipolar depression.Antidepressants were given to 84.8% (878/1036) of depressed patients: 58.9% of 93 bipolar-I, 80.1% of 117 bipolar-II, and 91.3% of 668 unipolar disorder cases. The 158 not given antidepressants had more manias/year, spent more months in mania and depression, and were far more likely t…

AdultMalemedicine.medical_specialtyBipolar DisorderMonoamine Oxidase InhibitorsAntidepressive Agents Tricyclicbehavioral disciplines and activitiesInternal medicinemental disordersmedicineHumansBipolar disorderPsychiatrySurvival analysisDepression (differential diagnoses)Depressive Disorder MajorManic MoodMiddle Agedmedicine.diseaseAntidepressive AgentsPsychiatry and Mental healthMoodTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptomPsychologyManiaSelective Serotonin Reuptake InhibitorsActa psychiatrica Scandinavica
researchProduct

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.

2006

SUMMARY Background: Venlafaxine (V) is a mixed serotoninand noradrenaline reuptake inhibitor used as afirst-line treatment of depressive disorders. It ismetabolized primarily by the highly polymorphiccytochrome P450 (CYP) enzyme CYP2D6 to yielda pharmacologically active metabolite, O-des-methylvenlafaxine (ODV), and to a lesser extentby CYP3A4, to yield N-desmethylvenlafaxine(NDV).Objectives: The aim of this study was to assesswhether the O-demethylation phenotype of V hasan impact on the pharmacokinetics and clinicaloutcome.Method: In 100 patients treated with V, serumconcentrations of V, ODV and NDV and theratios of concentrations ODV/V as a measure ofO-demethylation were determined. Indiv…

AdultMalemedicine.medical_specialtyCYP2D6AdolescentGenotypeVenlafaxine HydrochlorideVenlafaxineBiology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineDesvenlafaxine SuccinateGenotypemedicineHumansPharmacology (medical)Active metaboliteAgedPharmacologyDepressive DisorderPolymorphism GeneticfungiVenlafaxine HydrochlorideMiddle AgedCyclohexanols3. Good healthEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsAntidepressive Agents Second-GenerationFemaleReuptake inhibitor030217 neurology & neurosurgeryPharmacogeneticsmedicine.drugJournal of clinical pharmacy and therapeutics
researchProduct

Serum Concentrations of Fluvoxamine and Clinical Effects: A prospective open clinical trial

1998

This pilot study examined prospectively blood serum concentrations of fluvoxamine, side effects and therapeutic response after a fixed dosage of 100 mg fluvoxamine/day for 14 days. Twenty male and female patients who met the DSM-IV criteria of a major depression received 50 mg fluvoxamine b.i.d. for two weeks. On days 7 and 14 side effects and therapeutic response were registered and serum concentrations of fluvoxamine were determined. A Receiver Operating Characteristic (ROC) curve was constructed to determine a possible relationship between serum concentrations and clinical effects. The serum concentrations of fluvoxamine were highly variable, even when dosages were corrected for body wei…

AdultMalemedicine.medical_specialtyDosemedicine.medical_treatmentFluvoxamineGastroenterologyBlood serumInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesAgedAged 80 and overDepressive DisorderChemotherapymedicine.diagnostic_testReceiver operating characteristicbusiness.industryGeneral MedicineMiddle AgedClinical trialPsychiatry and Mental healthROC CurveFluvoxamineTherapeutic drug monitoringAnesthesiaAntidepressive Agents Second-GenerationFemaleDrug MonitoringbusinessReuptake inhibitormedicine.drugPharmacopsychiatry
researchProduct

Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus.

2007

Abstract BACKGROUND: The development of oesophageal adenocarcinoma is generally closely associated with the presence of a specialised intestinal-type epithelium such as that found in Barrett's oesophagus (BO). A particular histological condition is when the distal oesophagus showing cardiac and/or fundic mucosa without intestinal metaplasia cannot be defined as 'Barrett's mucosa' [condition that we call 'columnar-lined oesophagus' (CLO)] and up till now, there has been no agreement in literature about the management of this condition. Aurora-A overexpression leads to centrosome amplification, chromosomal instability and aneuploidy in mammalian cells. PATIENTS AND METHODS: A prospective stud…

AdultMalemedicine.medical_specialtyPathologyEsophageal NeoplasmsSettore MED/06 - Oncologia MedicaAneuploidySettore BIO/11 - Biologia MolecolareAdenocarcinomaProtein Serine-Threonine KinasesSettore MED/08 - Anatomia PatologicaGastroenterologyBarrett EsophagusAurora KinasesInternal medicineBiopsymedicineHumansAurora-A overexpression Barrett’s oesophagus cell cycle columnar-lined oesophagus p53 proteinProspective StudiesEsophagusMucous Membranemedicine.diagnostic_testEsophageal diseasebusiness.industryIntestinal metaplasiaHematologyMiddle Agedmedicine.diseasemedicine.anatomical_structureOncologyDysplasiaBarrett's esophagusGastroesophageal RefluxFemalebusinessImmunostainingBiomarkers
researchProduct

Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.

1998

Clozapine is a drug with many side effects, some of them with potentially hazardous outcome (e.g. seizures, agranulocytosis), if not carefully monitored. It has been shown that the metabolism of clozapine may be affected by concomitant treatment with selective serotonin reuptake inhibitors (SSRIs), while there have been reports of improved efficacy on negative symptomatology of clozapine in combination with SSRIs. Therefore, this prospective open clinical trial was performed to investigate the safety and tolerability of the coadministration of clozapine and paroxetine under control of serum concentrations of clozapine and its metabolites and the effect of this combination treatment on psych…

AdultMalemedicine.medical_specialtyPharmacologyPharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyClozapineBiological PsychiatryClozapinePharmacologymedicine.diseaseParoxetineClinical trialPsychiatry and Mental healthParoxetineNeurologyTolerabilitySchizophreniaConcomitantSchizophreniaDrug Therapy CombinationFemaleNeurology (clinical)PsychologySelective Serotonin Reuptake Inhibitorsmedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Outcome of intracytoplasmic sperm injection with and without polar body diagnosis of oocytes.

2008

Objective To compare the reproductive outcome of women undergoing intracytoplasmic sperm injection (ICSI) with or without polar body diagnosis of oocytes. Design Nonrandomized retrospective study. Setting University-based human genetic institute in collaboration with a private fertility center. Patient(s) Six hundred seven women undergoing ICSI with polar body diagnosis and 591 women undergoing ICSI without polar body diagnosis at the same time in the same fertility center. Intervention(s) Polar body testing of ICSI oocytes by five-color fluorescence in situ hybridization. Main Outcome Measure(s) Pregnancy rate (positive fetal heartbeats) and live-birth rate (of at least one child). Result(…

AdultMalemedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentmedia_common.quotation_subjectAneuploidyFertilityFertilization in VitroIntracytoplasmic sperm injectionPolar bodyAge DistributionPregnancyGermanymedicineHumansSperm Injections Intracytoplasmicreproductive and urinary physiologyZona Pellucidamedia_commonRetrospective StudiesGynecologyPregnancyurogenital systembusiness.industryObstetricsInfant NewbornPregnancy OutcomeObstetrics and GynecologyRetrospective cohort studyFertility Agents FemaleMiddle Agedmedicine.diseaseAneuploidyEmbryo TransferPregnancy rateReproductive Medicineembryonic structuresOocytesGestationFemaleLeuprolidebusinessLive BirthFertility and sterility
researchProduct

Female overweight is not associated with a higher embryo euploidy rate in first trimester miscarriages karyotyped by hysteroembryoscopy.

2011

Overweight women (body mass index ≥ 25 kg/m(2)) present an embryo euploidy rate in first trimester miscarriages similar to normoweight controls after a selective biopsy and karyotyping of embryo and/or chorion samples taken by hysteroembryoscopy.

AdultMalemedicine.medical_specialtyanimal structuresAneuploidyHysteroscopyOverweightPregnancyBiopsymedicineHumansRetrospective StudiesGynecologymedicine.diagnostic_testObstetricsbusiness.industryFetoscopyObstetrics and GynecologyEmbryoKaryotypeOverweightmedicine.diseaseAbortion SpontaneousFirst trimesterPregnancy Trimester FirstReproductive MedicineKaryotypingembryonic structuresFemalemedicine.symptomPloidybusinessBody mass indexFertility and sterility
researchProduct

Nonlinear pharmacokinetics of fluvoxamine and gender differences.

1998

This prospective study assessed fluvoxamine serum concentrations under two different fixed doses. The study included 15 male and female patients who met the DSM-III-R criteria for major depression. They were prescribed 50 mg fluvoxamine twice a day for 2 weeks and 100 mg twice a day thereafter. Drug monitoring was carried out on days 14 and 28. Fluvoxamine serum concentrations were highly variable between patients. After the dose was doubled, the serum concentrations of fluvoxamine increased disproportionately (mean, 3.4-fold), and there was a significantly (p < 0.05) more pronounced increase in men (4.6-fold) than in women (2.4-fold). These results provide evidence of nonlinear, sex-depend…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentFluvoxamineGastroenterologySex FactorsPharmacokineticsOral administrationInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyAgedPharmacologyAged 80 and overChemotherapyDepressive DisorderDose-Response Relationship Drugbusiness.industryNonlinear pharmacokineticsMiddle AgedDose–response relationshipFluvoxamineAnesthesiaAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugTherapeutic drug monitoring
researchProduct

Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome

1995

Objective To reevaluate the clinical significance of elevations of adrenal androgens in polycystic ovary syndrome (PCOS). Methods Thirty women with PCOS and ten ovulatory controls were evaluated. Serum dehydroepiandrosterone (DHEA) sulfate and 11β-hydroxyandrostenedione were measured before and after 3 and 6 months of GnRH agonist (GnRH-A) therapy. All controls and 15 women with PCOS received intravenous ACTH before and after GnRH-A therapy. Results Twenty-one (70%) of the women with PCOS had elevations of DHEA sulfate, and 16 (53%) had elevations in 11/3-hydroxyandrostenedione. Only two women with PCOS had normal values of both adrenal androgens. After GnRH-A therapy, only 11 subjects (37%…

Adultendocrine systemmedicine.medical_specialtyendocrine system diseasesmedicine.drug_classDehydroepiandrosteroneOvaryPeptide hormonechemistry.chemical_compoundDehydroepiandrosterone sulfateAdrenocorticotropic HormoneInternal medicinepolycyclic compoundsmedicineHumansAndrostenedioneTriptorelin PamoateDehydroepiandrosterone Sulfatebusiness.industryAndrostenedioneObstetrics and GynecologyDehydroepiandrosteroneAndrogenPolycystic ovaryAndrogen secretionmedicine.anatomical_structureEndocrinologychemistryCase-Control StudiesFemaleLeuprolidebusinesshormones hormone substitutes and hormone antagonistsPolycystic Ovary SyndromeObstetrics &amp; Gynecology
researchProduct